Allergan (AGN) Receives FDA Approval for OZURDEX(TM)
Down)
Allergan, Inc. (NYSE: AGN) today announced that the United States FDA has approved OZURDEX(TM) (dexamethasone intravitreal implant) 0.7 mg as the first drug therapy indicated for the treatment of macular edema following branch retinal vein occlusion or central retinal vein occlusion. Retinal vein occlusion, including BRVO and CRVO, is the second most common retinal vascular disease after diabetic retinopathy1 and is a significant cause of vision loss.
More from the release.
More from the release.
You May Also Be Interested In
- NFP Announces Marshall A. Heinberg Joins Board of Directors
- HeartWare (HTWR) Publishes Encouraging Data from ADVANCE in Advanced Heart Failure
- Salesforce.com Sees Tremendous Growth Across Europe, Increases Local Investment
Create E-mail Alert Related Categories
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
